Advertisement
Screener

PRECIGEN, INC. (PGEN) Investing Cash Flow

PRECIGEN, INC. Investing Cash Flow

PRECIGEN, INC. (PGEN) reported Investing Cash Flow of $47.66 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.

Financial Statements › Cash Flow › Investing Activities

us-gaap:NetCashProvidedByUsedInInvestingActivities · last filed 2026-08-04

  • PRECIGEN, INC. net cash provided by (used in) investing activities for the quarter ending 2026-06-30 was $26.69M, a 6.16% decline year-over-year.
  • PRECIGEN, INC. net cash provided by (used in) investing activities for the quarter ending 2026-03-31 was $20.97M.
  • PRECIGEN, INC. net cash provided by (used in) investing activities for the quarter ending 2025-12-31 was $39.87M.
  • PRECIGEN, INC. net cash provided by (used in) investing activities for the quarter ending 2025-09-30 was -$63.39M, a 1221.28% decline year-over-year.
  • PRECIGEN, INC. net cash provided by (used in) investing activities for fiscal 2025 was -$1.53M.
  • PRECIGEN, INC. net cash provided by (used in) investing activities for fiscal 2024 was -$20.71M.
  • PRECIGEN, INC. net cash provided by (used in) investing activities for fiscal 2023 was -$3.09M, a 101.36% decline from fiscal 2022.
  • PRECIGEN, INC. net cash provided by (used in) investing activities for fiscal 2022 was $226.42M.
Period endNet Cash Provided by (Used in) Investing Activities 3 monthNet Cash Provided by (Used in) Investing Activities 6 monthNet Cash Provided by (Used in) Investing Activities 9 monthNet Cash Provided by (Used in) Investing Activities 12 monthNet Cash Provided by (Used in) Investing Activities 12 month as first filed
2026-06-30$26.69M
derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04
$47.66M
10-Q · filed 2026-08-04
$87.52M
derived: sum of 3 quarters · filed 2026-08-04
$24.14M
derived: sum of 4 quarters · filed 2026-08-04
2026-03-31$20.97M
10-Q · filed 2026-05-13
$60.83M
derived: sum of 2 quarters · filed 2026-05-13
-$2.55M
derived: sum of 3 quarters · filed 2026-05-13
$25.89M
derived: sum of 4 quarters · filed 2026-08-04
2025-12-31$39.87M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-25
-$23.52M
derived: sum of 2 quarters · filed 2026-03-25
$4.92M
derived: sum of 3 quarters · filed 2026-08-04
-$1.53M
10-K · filed 2026-03-25
2025-09-30-$63.39M
derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13
-$34.94M
derived: sum of 2 quarters · filed 2026-08-04
-$41.40M
10-Q · filed 2025-11-13
-$106.77M
derived: sum of 4 quarters · filed 2026-08-04
2025-06-30$28.44M
derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04
$21.98M
10-Q · filed 2026-08-04
-$43.38M
derived: sum of 3 quarters · filed 2026-08-04
-$37.73M
derived: sum of 4 quarters · filed 2026-08-04
2025-03-31-$6.46M
10-Q · filed 2026-05-13
-$71.82M
derived: sum of 2 quarters · filed 2026-05-13
-$66.17M
derived: sum of 3 quarters · filed 2026-05-13
-$51.22M
derived: sum of 4 quarters · filed 2026-05-13
2024-12-31-$65.37M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-25
-$59.71M
derived: sum of 2 quarters · filed 2026-03-25
-$44.76M
derived: sum of 3 quarters · filed 2026-03-25
-$20.71M
10-K · filed 2026-03-25
2024-09-30$5.65M
derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13
$20.61M
derived: sum of 2 quarters · filed 2025-11-13
$44.65M
10-Q · filed 2025-11-13
$57.95M
derived: sum of 4 quarters · filed 2026-03-25
2024-06-30$14.96M
derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12
$39.00M
10-Q · filed 2025-08-12
$52.29M
derived: sum of 3 quarters · filed 2026-03-25
$62.82M
derived: sum of 4 quarters · filed 2026-03-25
2024-03-31$24.05M
10-Q · filed 2025-05-14
$37.34M
derived: sum of 2 quarters · filed 2026-03-25
$47.86M
derived: sum of 3 quarters · filed 2026-03-25
$71.37M
derived: sum of 4 quarters · filed 2026-03-25
2023-12-31$13.29M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-25
$23.82M
derived: sum of 2 quarters · filed 2026-03-25
$47.32M
derived: sum of 3 quarters · filed 2026-03-25
-$3.09M
10-K · filed 2026-03-25
2023-09-30$10.53M
derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14
$34.03M
derived: sum of 2 quarters · filed 2024-11-14
-$16.38M
10-Q · filed 2024-11-14
-$4.96M
derived: sum of 4 quarters · filed 2025-03-19
2023-06-30$23.50M
derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14
-$26.91M
10-Q · filed 2024-08-14
-$15.48M
derived: sum of 3 quarters · filed 2025-03-19
$166.37M
derived: sum of 4 quarters · filed 2025-03-19
2023-03-31-$50.41M
10-Q · filed 2024-05-14
-$38.99M
derived: sum of 2 quarters · filed 2025-03-19
$142.87M
derived: sum of 3 quarters · filed 2025-03-19
$159.44M
derived: sum of 4 quarters · filed 2025-03-19
2022-12-31$11.42M
derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-19
$193.28M
derived: sum of 2 quarters · filed 2025-03-19
$209.85M
derived: sum of 3 quarters · filed 2025-03-19
$226.42M
10-K · filed 2025-03-19
2022-09-30$181.85M
derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09
$198.43M
derived: sum of 2 quarters · filed 2023-11-09
$215.00M
10-Q · filed 2023-11-09
$230.93M
derived: sum of 4 quarters · filed 2024-03-19
2022-06-30$16.57M
derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-09
$33.14M
10-Q · filed 2023-08-09
$49.07M
derived: sum of 3 quarters · filed 2024-03-19
$71.08M
derived: sum of 4 quarters · filed 2024-03-19
2022-03-31$16.57M
10-Q · filed 2023-05-10
$32.50M
derived: sum of 2 quarters · filed 2024-03-19
$54.51M
derived: sum of 3 quarters · filed 2024-03-19
$71.13M
derived: sum of 4 quarters · filed 2024-03-19
2021-12-31$15.93M
derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-19
$37.94M
derived: sum of 2 quarters · filed 2024-03-19
$54.56M
derived: sum of 3 quarters · filed 2024-03-19
-$74.54M
10-K · filed 2024-03-19
2021-09-30$22.01M
derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09
$38.63M
derived: sum of 2 quarters · filed 2022-11-09
-$90.47M
10-Q · filed 2022-11-09
-$50.28M
derived: sum of 4 quarters · filed 2023-03-06
2021-06-30$16.62M
derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-08
-$112.48M
10-Q · filed 2022-08-08
-$72.30M
derived: sum of 3 quarters · filed 2023-03-06
-$72.12M
derived: sum of 4 quarters · filed 2023-03-06
2021-03-31-$129.10M
10-Q · filed 2022-05-09
-$88.92M
derived: sum of 2 quarters · filed 2023-03-06
-$88.74M
derived: sum of 3 quarters · filed 2023-03-06
-$64.77M
derived: sum of 4 quarters · filed 2023-03-06
2020-12-31$40.18M
derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-06
$40.37M
derived: sum of 2 quarters · filed 2023-03-06
$64.33M
derived: sum of 3 quarters · filed 2023-03-06
$27.78M
10-K · filed 2023-03-06
2020-09-30$181.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-08
$24.15M
derived: sum of 2 quarters · filed 2021-11-08
-$12.40M
10-Q · filed 2021-11-08
$42.10M
derived: sum of 4 quarters · filed 2022-03-01
2020-06-30$23.97M
derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-09
-$12.59M
10-Q · filed 2021-08-09
$41.92M
derived: sum of 3 quarters · filed 2022-03-01
$55.70M
derived: sum of 4 quarters · filed 2022-03-01
2020-03-31-$36.55M
10-Q · filed 2021-05-10
$17.96M
derived: sum of 2 quarters · filed 2022-03-01
$31.73M
derived: sum of 3 quarters · filed 2022-03-01
$16.71M
derived: sum of 4 quarters · filed 2022-03-01
2019-12-31$54.51M
derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01
$68.29M
derived: sum of 2 quarters · filed 2022-03-01
$53.26M
derived: sum of 3 quarters · filed 2022-03-01
$86.85M
10-K · filed 2022-03-01
2019-09-30$13.78M
derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-09
-$1.25M
derived: sum of 2 quarters · filed 2020-11-09
$32.34M
10-Q · filed 2020-11-09
$63.08M
derived: sum of 4 quarters · filed 2021-03-01
2019-06-30-$15.03M
derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-10
$18.57M
10-Q · filed 2020-08-10
$49.31M
derived: sum of 3 quarters · filed 2021-03-01
-$111.73M
derived: sum of 4 quarters · filed 2021-03-01
2019-03-31$33.59M
10-Q · filed 2020-05-11
$64.33M
derived: sum of 2 quarters · filed 2021-03-01
-$96.70M
derived: sum of 3 quarters · filed 2021-03-01
-$110.17M
derived: sum of 4 quarters · filed 2021-03-01
2018-12-31$30.74M
derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-01
-$130.29M
derived: sum of 2 quarters · filed 2021-03-01
-$143.76M
derived: sum of 3 quarters · filed 2021-03-01
-$151.21M
10-K · filed 2021-03-01
2018-09-30-$161.03M
derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-12
-$174.50M
derived: sum of 2 quarters · filed 2019-11-12
-$181.95M
10-Q · filed 2019-11-12
-$158.04M
derived: sum of 4 quarters · filed 2020-03-02
2018-06-30-$13.46M
derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-09
-$20.92M
10-Q · filed 2019-08-09
$2.99M
derived: sum of 3 quarters · filed 2020-03-02
$31.13M
derived: sum of 4 quarters · filed 2020-03-02
2018-03-31-$7.46M
10-Q · filed 2019-05-09
$16.46M
derived: sum of 2 quarters · filed 2020-03-02
$44.59M
derived: sum of 3 quarters · filed 2020-03-02
$62.32M
derived: sum of 4 quarters · filed 2020-03-02
2017-12-31$23.91M
derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-02
$52.05M
derived: sum of 2 quarters · filed 2020-03-02
$69.78M
derived: sum of 3 quarters · filed 2020-03-02
$104.33M
10-K · filed 2020-03-02
2017-09-30$28.14M
derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-08
$45.86M
derived: sum of 2 quarters · filed 2018-11-08
$80.42M
10-Q · filed 2018-11-08
$97.17M
derived: sum of 4 quarters · filed 2019-03-01
2017-06-30$17.73M
derived: 10-Q 6 month − 10-Q/A 3 month · filed 2018-08-13
$52.28M
10-Q · filed 2018-08-13
$69.03M
derived: sum of 3 quarters · filed 2019-03-01
$5.27M
derived: sum of 4 quarters · filed 2019-03-01
2017-03-31$34.55M
10-Q/A · filed 2018-08-13
$51.31M
derived: sum of 2 quarters · filed 2019-03-01
-$12.46M
derived: sum of 3 quarters · filed 2019-03-01
$2.28M
derived: sum of 4 quarters · filed 2019-03-01
2016-12-31$16.75M
derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-01
-$47.02M
derived: sum of 2 quarters · filed 2019-03-01
-$32.27M
derived: sum of 3 quarters · filed 2019-03-01
-$28.39M
10-K · filed 2019-03-01
2016-09-30-$63.77M
derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-09
-$49.02M
derived: sum of 2 quarters · filed 2017-11-09
-$45.14M
10-Q · filed 2017-11-09
-$47.07M
derived: sum of 4 quarters · filed 2018-03-01
2016-06-30$14.74M
derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-09
$18.62M
10-Q · filed 2017-08-09
$16.70M
derived: sum of 3 quarters · filed 2018-03-01
-$222.81M
derived: sum of 4 quarters · filed 2018-03-01
2016-03-31$3.88M
10-Q · filed 2017-05-10
$1.95M
derived: sum of 2 quarters · filed 2018-03-01
-$237.56M
derived: sum of 3 quarters · filed 2018-03-01
-$229.33M
derived: sum of 4 quarters · filed 2018-03-01
2015-12-31-$1.93M
derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-01
-$241.44M
derived: sum of 2 quarters · filed 2018-03-01
-$233.21M
derived: sum of 3 quarters · filed 2018-03-01
-$259.25M
10-K · filed 2018-03-01
-$260.81M
10-K · filed 2016-02-29
2015-09-30-$239.51M
derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-09
-$231.28M
derived: sum of 2 quarters · filed 2016-11-09
-$257.32M
10-Q · filed 2016-11-09
-$246.85M
derived: sum of 4 quarters · filed 2017-03-01
2015-06-30$8.22M
derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-09
-$17.81M
10-Q · filed 2016-08-09
-$7.34M
derived: sum of 3 quarters · filed 2017-03-01
2015-03-31-$26.03M
10-Q · filed 2016-05-10
-$15.57M
derived: sum of 2 quarters · filed 2017-03-01
2014-12-31$10.46M
derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-01
-$26.03M
10-K · filed 2017-03-01
2014-09-30-$36.49M
10-Q · filed 2015-11-09
2013-12-31-$1.96M
derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-29
-$128.35M
derived: sum of 2 quarters · filed 2016-02-29
-$223.66M
10-K · filed 2016-02-29
2013-09-30-$126.39M
derived: 10-Q 9 month − 10-Q/A 6 month · filed 2013-11-07
-$221.70M
10-Q · filed 2013-11-07
2013-06-30-$95.31M
10-Q/A · filed 2013-10-21
2012-12-31-$6.54M
derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-02
-$6.71M
derived: sum of 2 quarters · filed 2015-03-02
-$23.64M
10-K · filed 2015-03-02
2012-09-30-$170.00K
derived: 10-Q 9 month − 10-Q/A 6 month · filed 2013-11-07
-$17.10M
10-Q · filed 2013-11-07
2012-06-30-$16.93M
10-Q/A · filed 2013-10-21
2011-12-31-$64.10M
10-K · filed 2014-03-31

Similar stocks

Stock NameCountryMarket CapPE Ratio
NewAmsterdam Pharma Co N.V. (NAMS)$2.719B-15.37
MBX Biosciences, Inc. (MBX)United States$2.664B-25.36
Disc Medicine, Inc. (IRON)United States$2.553B-11.40
Immunome Inc. (IMNM)United States$2.538B-9.45
SUPERNUS PHARMACEUTICALS, INC. (SUPN)United States$2.517B-24.63
Nurix Therapeutics, Inc. (NRIX)United States$2.457B-5.39
Dyne Therapeutics, Inc. (DYN)United States$3.084B-7.09
SELLAS Life Sciences Group, Inc. (SLS)United States$2.420B-91.87
uniQure N.V. (QURE)$2.416B-4.93
Vera Therapeutics, Inc. (VERA)United States$2.402B-7.67